secwatch.observer — SEC 8-K summary
======================================

Issuer:     HERON THERAPEUTICS, INC. /DE/ (HRTX)
CIK:        0000818033
Form:       8-K
Filed at:   2024-05-07T23:59:59+00:00
Accession:  0000950170-24-053963
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Heron Q1 2024 net product sales $34.7M (+17% YoY); net loss per share improves to $(0.02)
--------------------------------------------------------------------------------

- Net product sales $34.7M vs $29.6M YoY; net loss per share $(0.02) vs $(0.27).
- Gross margin improved to 76% in Q1 2024 from 43% in Q1 2023.
- ZYNRELEF net sales $5.0M (+43% YoY); FDA expanded indication approved Jan 23, 2024, covering soft tissue and orthopedic procedures.
- Reaffirmed FY2024 guidance: product revenues $138-158M, adjusted operating expenses $108-116M, adjusted EBITDA $(22)-$3M.
- Partnership with CrossLink Life Sciences; 191 CrossLink sales reps trained and engaged with physicians.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/818033/000095017024053963/0000950170-24-053963-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/818033/000095017024053963/hrtx-20240507.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-053963

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer